Ekaterina Vasilieva
Overview
Explore the profile of Ekaterina Vasilieva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klyusov N, Garin N, Usenyuk-Kravchuk S, Vasilieva E, Ustinov K
Biomimetics (Basel)
. 2023 Aug;
8(4).
PMID: 37622965
The paper explores the potential of the biomorphic approach to context-based design with a focus on special-purpose mobility in the Arctic. The study seeks to contribute to the analytical and...
2.
Efremova I, Maslennikov R, Poluektova E, Vasilieva E, Zharikov Y, Suslov A, et al.
World J Gastroenterol
. 2023 Jun;
29(22):3400-3421.
PMID: 37389240
Small intestinal bacterial overgrowth (SIBO) is defined as an increase in the bacterial content of the small intestine above normal values. The presence of SIBO is detected in 33.8% of...
3.
Dmitrieva K, Maslennikov R, Vasilieva E, Aliev S, Bakhitov V, Marcinkevich V, et al.
J Infect Public Health
. 2023 Apr;
16(6):922-927.
PMID: 37086551
Objectives: The aim is to study impact of vaccination against the novel coronavirus disease (COVID-19) with Sputnik V on mortality during the period of predominance of the delta variant of...
4.
Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V, et al.
Eur Cytokine Netw
. 2021 Aug;
32(1):8-14.
PMID: 34346869
Cytokine release syndrome is a serious complication of the new coronavirus infection (COVID-19). The aim of the study was to assess effectiveness and safety of the IL-17 antagonist nekatimab for...
5.
Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V, et al.
Pulm Pharmacol Ther
. 2021 May;
69:102039.
PMID: 34023513
Background And Aim: Cytokine release syndrome is a dangerous complication of the coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety of tofacitinib in the management...